Biosimilar Red Tape Elimination Act simplifies the process for determining interchangeability of biological products.
The Biosimilar Red Tape Elimination Act aims to streamline the requirements for determining the interchangeability of biological products with their reference products. It mandates the Food and Drug Administration to update existing guidance within 18 months of the Act's enactment, specifically revising the "Considerations in Demonstrating Interchangeability With a Reference Product" guidance documents. The Act also modifies the criteria for deeming a biological product interchangeable with its reference product, affecting both products licensed before and after the Act's enactment.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.